Valenta Pharm JSC: Communicable Diseases trials
The registry lists 11 Communicable Diseases studies with Valenta Pharm JSC as lead sponsor. 2 are open to participants now and 0 have results posted.
Phase 2 2Phase 3 7Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral InfectionsRecruitingNCT06379542Phase 3
- Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Viral InfectionsRecruitingNCT06315400Phase 4
- A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory InfectionsCompletedNCT05544916Phase 3
- Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral InfectionCompletedNCT05273619Phase 3
- Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral InfectionCompletedNCT05269329Phase 2
- Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral InfectionsCompletedNCT05269290Phase 3
- A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory InfectionsCompletedNCT05030324Phase 2
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.CompletedNCT03206346Phase 3
- Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.CompletedNCT03191097Phase 3
- Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral InfectionsCompletedNCT03189537Phase 3
- Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in AdultsCompletedNCT03154515Phase 4